It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Chronic obstructive pulmonary disease (COPD) is a leading cause of death worldwide, however our understanding of cell specific mechanisms underlying COPD pathobiology remains incomplete. Here, we analyze single-cell RNA sequencing profiles of explanted lung tissue from subjects with advanced COPD or control lungs, and we validate findings using single-cell RNA sequencing of lungs from mice exposed to 10 months of cigarette smoke, RNA sequencing of isolated human alveolar epithelial cells, functional in vitro models, and in situ hybridization and immunostaining of human lung tissue samples. We identify a subpopulation of alveolar epithelial type II cells with transcriptional evidence for aberrant cellular metabolism and reduced cellular stress tolerance in COPD. Using transcriptomic network analyses, we predict capillary endothelial cells are inflamed in COPD, particularly through increased CXCL-motif chemokine signaling. Finally, we detect a high-metallothionein expressing macrophage subpopulation enriched in advanced COPD. Collectively, these findings highlight cell-specific mechanisms involved in the pathobiology of advanced COPD.
Chronic obstructive pulmonary disease is a leading cause of death worldwide, while our understanding of cell-specific mechanisms underlying its pathobiology remains incomplete. Here the authors perform scRNA-seq of human lung tissue to identify transcriptional changes in alveolar niche cells associated with the disease.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details









1 Yale School of Medicine, Pulmonary, Critical Care and Sleep Medicine, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710)
2 Yale School of Medicine, Pulmonary, Critical Care and Sleep Medicine, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710); Medical University of Graz, Division of Pharmacology, Otto Loewi Research Center, Graz, Austria (GRID:grid.11598.34) (ISNI:0000 0000 8988 2476)
3 Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, USA (GRID:grid.239424.a) (ISNI:0000 0001 2183 6745); Boston University School of Medicine, The Pulmonary Center and Department of Medicine, Boston, USA (GRID:grid.189504.1) (ISNI:0000 0004 1936 7558); QIMR Berghofer Medical Research Institute, Herston, Australia (GRID:grid.1049.c) (ISNI:0000 0001 2294 1395)
4 Yale School of Medicine, Pulmonary, Critical Care and Sleep Medicine, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710); German Lung Research Center (DZL), Department of Respiratory Medicine, Hannover Medical School and Biomedical Research in End-stage and Obstructive Lung Disease Hannover, Hannover, Germany (GRID:grid.47100.32)
5 Baylor College of Medicine, Pulmonary, Critical Care and Sleep Medicine, Houston, USA (GRID:grid.39382.33) (ISNI:0000 0001 2160 926X)
6 Yale School of Medicine, Pulmonary, Critical Care and Sleep Medicine, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710); The First Affiliated Hospital of Chongqing Medical University, Department of Thoracic and Cardiovascular Surgery, Chongqing, China (GRID:grid.452206.7) (ISNI:0000 0004 1758 417X)
7 Mount Sinai Medical Center, Department of Internal Medicine, Miami, USA (GRID:grid.410396.9) (ISNI:0000 0004 0430 4458)
8 Brigham and Women’s Hospital, Harvard Medical School, Division of Pulmonary and Critical Care Medicine, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
9 Intomics A/S, Lyngby, Denmark (GRID:grid.38142.3c)
10 Yale University, Department of Biomedical Engineering, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710); Yale School of Medicine, Medical Scientist Training Program, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710)
11 Yale University, Department of Biomedical Engineering, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710)
12 Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, USA (GRID:grid.239424.a) (ISNI:0000 0001 2183 6745); Boston University School of Medicine, The Pulmonary Center and Department of Medicine, Boston, USA (GRID:grid.189504.1) (ISNI:0000 0004 1936 7558)
13 Intomics A/S, Lyngby, Denmark (GRID:grid.189504.1)